Prima BioMed to Host Investor Days in Australia

(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwire) -- 01/23/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") is pleased to announce upcoming investor days at several major Australian cities in February.

Prima CEO, Matthew Lehman will host the sessions, to be held in Sydney, Melbourne, Brisbane and Perth, in the week commencing 4 February 2013.

Mr. Lehman will provide an update on the Company's business and attendees will have an opportunity for Q&A.



Parmelia Hilton Hotel, 14 Mill St, Perth
10.00am - 11.30am local time

Westin Melbourne Hotel, 205 Collins St, Melbourne
10.30am - 12.00noon local time

Hilton Brisbane Hotel, 190 Elizabeth St, Brisbane
10.00am - 11.30am local time

Radisson Blu Hotel, 27 O'Connell St, Sydney
10.30am - 12.00noon local time

Shareholders and other interested parties are kindly requested to help assure appropriate accommodations by sending an RSVP by email to and identify the city of attendance by Friday 1st February.

Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.



Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061


Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574


Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 24.01.2013 - 01:15 Uhr
Sprache: Deutsch
News-ID 222474
Anzahl Zeichen: 0

contact information:
Town:

SYDNEY, AUSTRALIA

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 243 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Prima BioMed to Host Investor Days in Australia"
steht unter der journalistisch-redaktionellen Verantwortung von

Prima BioMed (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Prima BioMed Raises A$2.0 Million Through Placement to Leading Australian Instit ...

SYDNEY, AUSTRALIA -- (Marketwired) -- 10/30/15 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, announces that it has raised A$2.0 million via an equity placement at A$0.05 per ordinary ASX listed share to a leading ...

Prima BioMed Gains Belgian Regulatory Approval to Commence a Registration Phase ...

SYDNEY, AUSTRALIA -- (Marketwired) -- 10/27/15 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)Belgium's Federal Agency for Medicines and Health Products Approved the Commencement of the AIPAC StudyIMP321 Phase IIb trial initiation is expected bef ...

Prima BioMed Raises A$1.55M Through Placement to Sophisticated European Healthca ...

SYDNEY, AUSTRALIA -- (Marketwired) -- 10/13/15 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), a leading immuno-oncology company, announces that it has raised EUR 1M (approx. A$1.55M) via a placement of ...

Alle Meldungen von Prima BioMed